Marco Lupattelli1, Matthew Alcusky2, Cynthia Aristei3, Rita Bellavita1, Barbara A Jereczek-Fossa4, John McAna2, Timothy N Showalter5, Vittorio Maio2. 1. 1 Radiation Oncology Center, Perugia General Hospital, Perugia, Italy. 2. 2 College of Population Health, Thomas Jefferson University, Philadelphia, PA, USA. 3. 3 Radiation Oncology Section, Department of Surgery and Biomedical Sciences, University of Perugia and Perugia General Hospital, Perugia, Italy. 4. 4 Department of Radiotherapy, European Institute of Oncology, Università degli Studi di Milano, Milan, Italy. 5. 5 Radiation Oncology, University of Virginia Health System, Charlottesville, VA, USA.
Abstract
OBJECTIVE: Evidence regarding adjuvant radiation therapy (ART) and salvage radiation therapy (SRT) following radical prostatectomy (RP) for prostate cancer is inconsistent. The study objectives were to collect survey information on Italian radiation oncologists' (RO) beliefs regarding the use of ART and SRT following RP and to compare the results of Italian RO with those of American RO available from an analogous survey. METHODS: A modified version of a US-based questionnaire captured attitudes and clinical approaches regarding post-RP RT of all 716 RO practicing in 147 radiation oncology centres in Italy. Bivariate analyses compared the responses of Italian RO with those of American RO retrieved from a previously published study. RESULTS: Analysable questionnaires were completed by 153 Italian RO (response rate, 21%). Variations in practice were found for RT use, timing, dosage and technique. All Italian RO supported ART use, although factors influencing the decision to initiate ART varied. Most RO (81%) would wait 3-6 months after surgery before beginning RT. Compared with Italian RO, more American RO believed ART improves survival outcomes (70% vs 35%, p < 0.001), would initiate ART based solely on adverse pathological features (79% vs 69%, p < 0.001) and would initiate SRT based on any detectable prostate-specific antigen (37% vs 11%, p < 0.001). CONCLUSION: Italian RO strongly supported ART, but their approach to patient selection for ART and SRT varied. Striking differences between Italian RO and American RO regarding ART and SRT practices were found. ADVANCE IN KNOWLEDGE: Differential RT practices and perceptions exist among RO internationally. Clinical studies must inform evidence-based guidelines to harmonize the use of post-RP RT.
OBJECTIVE: Evidence regarding adjuvant radiation therapy (ART) and salvage radiation therapy (SRT) following radical prostatectomy (RP) for prostate cancer is inconsistent. The study objectives were to collect survey information on Italian radiation oncologists' (RO) beliefs regarding the use of ART and SRT following RP and to compare the results of Italian RO with those of American RO available from an analogous survey. METHODS: A modified version of a US-based questionnaire captured attitudes and clinical approaches regarding post-RP RT of all 716 RO practicing in 147 radiation oncology centres in Italy. Bivariate analyses compared the responses of Italian RO with those of American RO retrieved from a previously published study. RESULTS: Analysable questionnaires were completed by 153 Italian RO (response rate, 21%). Variations in practice were found for RT use, timing, dosage and technique. All Italian RO supported ART use, although factors influencing the decision to initiate ART varied. Most RO (81%) would wait 3-6 months after surgery before beginning RT. Compared with Italian RO, more American RO believed ART improves survival outcomes (70% vs 35%, p < 0.001), would initiate ART based solely on adverse pathological features (79% vs 69%, p < 0.001) and would initiate SRT based on any detectable prostate-specific antigen (37% vs 11%, p < 0.001). CONCLUSION: Italian RO strongly supported ART, but their approach to patient selection for ART and SRT varied. Striking differences between Italian RO and American RO regarding ART and SRT practices were found. ADVANCE IN KNOWLEDGE: Differential RT practices and perceptions exist among RO internationally. Clinical studies must inform evidence-based guidelines to harmonize the use of post-RP RT.
Authors: Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; F Zattoni; Nicolas Mottet Journal: Eur Urol Date: 2013-10-06 Impact factor: 20.096
Authors: P J Van Cangh; F Richard; F Lorge; Y Castille; A Moxhon; R Opsomer; L De Visscher; F X Wese; P Scaillet Journal: J Urol Date: 1998-01 Impact factor: 7.450
Authors: Michel Bolla; Hein van Poppel; Bertrand Tombal; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Marc Colombel; Cees van de Beek; Paul Verhagen; Alphonsus van den Bergh; Cora Sternberg; Thomas Gasser; Geertjan van Tienhoven; Pierre Scalliet; Karin Haustermans; Laurence Collette Journal: Lancet Date: 2012-10-19 Impact factor: 79.321
Authors: Michel Bolla; Hein van Poppel; Laurence Collette; Paul van Cangh; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Jean-Marie Maréchal; Pierre Scalliet; Karin Haustermans; Marianne Piérart Journal: Lancet Date: 2005 Aug 13-19 Impact factor: 79.321
Authors: Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford Journal: JAMA Date: 2006-11-15 Impact factor: 56.272
Authors: R K Valicenti; L G Gomella; M Ismail; S G Mulholland; S Strup; R O Petersen; B W Corn; J D Lu Journal: Urology Date: 1998-12 Impact factor: 2.649
Authors: Ian M Thompson; Richard K Valicenti; Peter Albertsen; Brian J Davis; S Larry Goldenberg; Carol Hahn; Eric Klein; Jeff Michalski; Mack Roach; Oliver Sartor; J Stuart Wolf; Martha M Faraday Journal: J Urol Date: 2013-05-21 Impact factor: 7.450
Authors: F Alongi; B De Bari; P Franco; P Ciammella; T Chekrine; L Livi; B A Jereczek-Fossa; A R Filippi Journal: Radiol Med Date: 2013-01-28 Impact factor: 3.469
Authors: Luke T Lavallée; Dean Fergusson; Ranjeeta Mallick; Renée Grenon; Scott C Morgan; Franco Momoli; Kelsey Witiuk; Chris Morash; Ilias Cagiannos; Rodney H Breau Journal: PLoS One Date: 2013-11-04 Impact factor: 3.240